ZLAB241220C15000
- 0.00
- 0.000.00%
Zai Lab Newsroom
Zai Lab's AUGTYRO For ROS1+ NSCLC Added To China's National Reimbursement Drug List
Express News | Zai Lab Announces the Inclusion of Augtyro® (Repotrectinib) for Ros1+ Nsclc and Other Updates in China’s National Reimbursement Drug List
Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Monday Trading
Zai Lab Raises $216 Million Through ADS Offering
Hong Kong stocks fluctuate | Zai Lab (09688) rises over 5% as it cooperates with Pfizer on the new antibacterial drug in mainland China.
zai lab (09688) rose more than 5%, as of the deadline, it increased by 5.26%, closing at 20.8 Hong Kong dollars, with a turnover of 7.8692 million Hong Kong dollars.
Zai Lab (09688.HK) has completed the offering of American depositary shares and the full exercise of options.
Grantham 22nd November News: zai lab (09688.HK) announced with pleasure that on 18th November 2024 (USA Eastern Time), it completed the public offering of 7,843,137 American Depositary Shares at a price of $25.50 per ADS (equivalent to approximately HK$19.84 per share (calculated based on the ratio of one ADS to every ten shares)). In addition, the underwriters have fully exercised their options to purchase an additional 1,176,470 ADS at the offer price minus the underwriting discount and commissions. Regarding the options of American Depositary Shares.
Sector Update: Health Care Stocks Rise Pre-Bell Thursday
Zai Lab, Pfizer Enter Collaboration for Xacduro
Express News | Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug Xacduro® (Sulbactam-Durlobactam)
China ADRs Have Increased to the Largest Share Since Late 2021 – GS
Zai Lab Grants Share Units to Employees
Zai Lab Announces Completion Of Offering Of About 7.8 Mln ADSs, Stock Down
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
Zai Lab Ltd Announces Major Share Offering
zai lab (09688.HK) received jpmorgan's shareholding of 1.1831 million shares.
According to the latest equity disclosure data from the Stock Exchange on November 18, 2023, zai lab (09688.HK) was increased in good holdings by JPMorgan Chase & Co. at an average price of HKD 24.5597 per share, acquiring 1.1831 million shares, involving approximately HKD 29.0566 million on November 11, 2024. Following the increase, the latest number of good holdings by JPMorgan Chase & Co. is 139,561,482 shares, with the proportion of good holdings rising from 13.89% to 14.01%.
Asian Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Down Over 3% for Week
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday
Analyst Estimates: Here's What Brokers Think Of Zai Lab Limited (NASDAQ:ZLAB) After Its Third-Quarter Report
Goldman Sachs, Jefferies Among Banks Acting as Underwriters to Zai Lab Deal
Zai Lab to Use Proceeds to Meet General Corporate Needs